Analysis of breath volatile organic compounds as a noninvasive tool to diagnose nonalcoholic fatty liver disease in children

European Journal of Gastroenterology and Hepatology

Volumn 26, Issue 1, 2014, Pages 82-87

  Alkhouri, Naim ^a,c   Cikach, Frank ^a   Eng, Katharine ^a   Moses, Jonathan ^a   Patel, Nishaben ^a   Yan, Chen ^a   Hanouneh, Ibrahim ^c   Grove, David ^a   Lopez, Rocio ^b   Dweik, Raed ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Quantitative Health Sciences ^*  (United States)

^c Digestive Disease Institute   (United States)

Author keywords

Biomarker; Breath testing; Children; Nonalcoholic fatty liver disease; Volatile organic compounds

Indexed keywords

1 DECENE; 1 HEPTENE; 1 OCTEN 3 OL; 2 NONENE; 2 PROPANOL; 3 METHYLHEXANE; ACETALDEHYDE; ACETONE; ACRYLONITRILE; ALCOHOL; AMMONIA; BENZENE; CARBON DISULFIDE; DIMETHYL SULFIDE; ETHANE; HYDROGEN SULFIDE; ISOPRENE; PENTANE; TRIETHYLAMINE; TRIMETHYLAMINE; UNCLASSIFIED DRUG; VOLATILE ORGANIC COMPOUND;

ADOLESCENT; AFRICAN AMERICAN; ARTICLE; BREATH ANALYSIS; CHILDHOOD DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ECHOGRAPHY; FEMALE; HUMAN; MALE; MASS SPECTROMETRY; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL;

ADOLESCENT; AGE FACTORS; AREA UNDER CURVE; BIOLOGICAL MARKERS; BREATH TESTS; CHILD; CROSS-SECTIONAL STUDIES; EXHALATION; FATTY LIVER; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; METABOLOMICS; OBESITY; PREDICTIVE VALUE OF TESTS; ROC CURVE; VOLATILE ORGANIC COMPOUNDS;

EID: 84889264686     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283650669     Document Type: Article

References (21)

1. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics 2006; 118:1388-1393. (Pubitemid 46393782)
2. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346:1221-1231.
3. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 2009; 58:1538-1544.
4. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40:1387-1395. (Pubitemid 39657013)
5. Shannon A, Alkhouri N, Carter-Kent C, Monti L, Devito R, Lopez R, et al. Ultrasonographic quantitative estimation of hepatic steatosis in children with NAFLD. J Pediatr Gastroenterol Nutr 2011; 53:190-195.
6. Mashir A, Dweik RA. Exhaled breath analysis: the new interface between medicine and engineering. Adv Powder Technol 2009; 20:420-425.
7. Paschke KM, Mashir A, Dweik RA. Clinical applications of breath testing. F1000 Med Rep 2010; 2:56.
8. Ford ES, Ajani UA, Mokdad AH. The metabolic syndrome and concentrations of C-reactive protein among U.S. youth. Diabetes Care 2005; 28:878-881. (Pubitemid 40434489)
9. Mashir A, Paschke KM, van Duin D, Shrestha NK, Laskowski D, Storer MK, et al. Effect of the influenza A (H1N1) live attenuated intranasal vaccine on nitric oxide (FE(NO)) and other volatiles in exhaled breath. J Breath Res 2011; 5:037107.
10. Prince BJ, Milligan DB, McEwan MJ. Application of selected ion flow tube mass spectrometry to real-time atmospheric monitoring. Rapid Commun Mass Spectrom 2010; 24:1763-1769.
11. Smith D, Spanel P. Selected ion flow tube mass spectrometry (SIFT-MS) for on-line trace gas analysis. Mass Spectrom Rev 2005; 24:661-700. (Pubitemid 41615714)
12. Shirasu M, Touhara K. The scent of disease: volatile organic compounds of the human body related to disease and disorder. J Biochem 2011; 150:257-266.
13. Wilson HK, Monster AC. New technologies in the use of exhaled breath analysis for biological monitoring. Occup Environ Med 1999; 56:753-757. (Pubitemid 29488285)
14. Kushch I, Arendacka B, Stolc S, Mochalski P, Filipiak W, Schwarz K, et al. Breath isoprene - aspects of normal physiology related to age, gender and cholesterol profile as determined in a proton transfer reaction mass spectrometry study. Clin Chem Lab Med 2008; 46:1011-1018. (Pubitemid 352000486)
15. Simonen P, Kotronen A, Hallikainen M, Sevastianova K, Makkonen J, Hakkarainen A, et al. Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity. J Hepatol 2011; 54:153-159.
16. Salerno-Kennedy R, Cashman KD. Potential applications of breath isoprene as a biomarker in modern medicine: a concise overview. Wien Klin Wochenschr 2005; 117 (5-6):180-186. (Pubitemid 40645909)
17. Buszewski B, Kesy M, Ligor T, Amann A. Human exhaled air analytics: biomarkers of diseases. Biomed Chromatogr 2007; 21:553-566. (Pubitemid 46937852)
18. Miekisch W, Schubert JK, Noeldge-Schomburg GF. Diagnostic potential of breath analysis - focus on volatile organic compounds. Clin Chim Acta 2004; 347 (1-2):25-39. (Pubitemid 39099603)
19. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011; 472:57-63.
20. Enderby B, Lenney W, Brady M, Emmett C, Spanel P, Smith D. Concentrations of some metabolites in the breath of healthy children aged 7-18 years measured using selected ion flow tube mass spectrometry (SIFT-MS). J Breath Res 2009; 3:036001.
21. Nair S, Cope K, Risby TH, Diehl AM. Obesity and female gender increase breath ethanol concentration: potential implications for the pathogenesis of nonalcoholic steatohepatitis. Am J Gastroenterol 2001; 96:1200-1204. (Pubitemid 32319161)